New Drugs Celebrated as a 'Major Shift' in Treating Drug-Resistant Gonorrhoea
The initial novel therapies for gonorrhoea in many years are being described as a "significant breakthrough" in the effort against increasingly resistant strains of the bacteria, according to researchers.
A Worldwide Challenge
Gonorrhoea infections are escalating around the world, with figures suggesting over 82 million new cases per year. Notably increased rates are reported in the African continent and nations within the WHO's Western Pacific region, which includes China and Mongolia to New Zealand. In England, cases have hit a all-time high, while figures across Europe in 2023 were three times higher compared to those in 2014.
“The approval of novel therapies for gonorrhoea is an critical and opportune advancement in the context of growing infection rates, the spread of superbugs and the very limited treatment choices currently available.”
Health officials are increasingly worried about the rise in treatment-resistant strains. The WHO has listed it as a "priority pathogen". Recent surveillance revealed that the effectiveness of standard treatments like ceftriaxone and cefixime had risen sharply between 2022 and 2024.
A Pair of Novel Treatment Options Receive Clearance
Zoliflodacin, alternatively called Nuzolvence, was approved by the US Food and Drug Administration in recent days for treating gonorrhoea. This STI can lead to serious health problems, including infertility. Researchers anticipate that targeted use of this new drug will help slow the spread of drug resistance.
Another new antibiotic, created by the drugmaker GlaxoSmithKline, was also approved in close succession. This treatment, which is additionally indicated for UTIs, was proven in research to be effective against drug-resistant strains of the gonorrhoea bacteria.
A Novel Development Model
This new treatment stemmed from a new, not-for-profit approach for drug creation. The charitable organization Global Antibiotic Research & Development Partnership partnered with the pharmaceutical company its industry partner to see it through.
“This approval represents a major breakthrough in the therapy of highly resistant gonorrhoea, which up to this point has been outpacing medical innovation.”
Research Study Data and Global Access
Based on findings published in a major medical journal, zoliflodacin eradicated over nine in ten of uncomplicated infections. This establishes an similar efficacy with the current standard treatment, which combines a dual-drug approach. The research included hundreds of volunteers from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.
As part of the agreement of its collaboration, the non-profit has the authority to license and sell the drug in many regions with limited resources.
Medical professionals on the front lines have shared optimism. Having a easy-to-administer therapy like this is seen as a "game-changer" for public health efforts. This is viewed as vital to alleviate the strain of the infection for people and to prevent the spread of untreatable gonorrhoea globally.